Skip to main content
. 2011 Oct 14;17(38):4321–4333. doi: 10.3748/wjg.v17.i38.4321

Figure 3.

Figure 3

Lamivudine treatment vs hepatitis B immunoglobulin in interruption of hepatitis B virus mother-to-child transmission as indicated by newborn serum hepatitis B surface antigen or hepatitis B virus DNA. CI: Confidence interval; HBIG: Hepatitis B immunoglobulin; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; HBV: Hepatitis B virus; M-H random: Mantel-Haenszel random-effects model; RR: Risk ratio.